Prognostic Marker Identified for Invasive Bladder Cancer by Angela Mohan on June 1, 2021 at 12:56 PM
In the new study 32 patients developed recurrent disease and 15 patients showed progression.
A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.
Dr. Takashi Kawahara from The Yokohama City University Medical Center said, Bladder cancer is the eleventh most common malignant disease in the world, and non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases.
The serum aspartate aminotransaminase /alanine aminotransaminase ratio was first reported by De Ritis in 1957, since then this ratio has been called the De Ritis ratio.
Role of Biomarkers In Assessing Renal Injury in Cancer Patients by Angela Mohan on February 4, 2021 at 11:03 AM
Kidney International Reports. Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer, says Sandra Herrmann, M.D., a Mayo Clinic nephrologist and the study s senior author. In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis.
Dr. Herrmann says a kidney biopsy is the gold standard to diagnose this condition. However, a kidney biopsy is an invasive procedure that some patients may not be able to undergo because of the risk of bleeding.
Researchers Uncover Promising Combination for Renal Cancer by Angela Mohan on January 21, 2021 at 12:29 PM
Loss of ACE2 mediates resistance to classical treatments to renal cell carcinoma (RCC) , and treatment with a drug that could downstream ACE2, can improve tumor responses in RCC and prolong survival.
Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent.
Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches.